Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 22, 2025 17:15 ET | Source: ImCheck Therapeutics SAS

ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy at ASCO 2025

ImCheck Reports High Remission Rates in AML Patientswith ICT01 Combination Therapy at ASCO 2025 ICT01 in combination with azacitidine and venetoclax (Aza-Ven) achieves unprecedented high remission...
March 05, 2024 17:10 ET | Source: Crossbow Therapeutics

Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets

Crossbow Therapeutics today announced the nomination of its first development candidate, CBX-250, a T-cell engager for the treatment of myeloid leukemia.